Premier Biomedical, Inc. (BIEI)

0.0016 -0.0000 (-1.87%) 收市：03:02PM EDT

Premier Biomedical, Inc.

PO Box 25
Jackson Center, PA 16133
United States
724 633 7033
https://www.premierbiomedical.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. David Caplan	President, Chairman of the Board of Directors, Secretary & Treasurer	無	無	無
Mr. Gustavo Carreño	Chief Technology Officer	無	無	無
Mr. Carl Eller	Marketing & Planning Vice-President	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.

公司管治

截至 無 止，Premier Biomedical, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。